THERMOCOOL SMARTTOUCH SF Catheter
Biosense Webster, Inc. · Decision date Sep 2, 2026
What did the FDA approve?
This supplement to PMA P030031 records a labeling change for the THERMOCOOL SMARTTOUCH SF catheter. The FDA database lists the supplement type as "Normal 180 Day Track" and the reason as "Labeling Change - Indications/instructions/shelf life/tradename." The exact labeling element that changed is not specified in the supplied fields, so the specific revised indication, instruction, shelf life, or trade name cannot be identified from this record alone.
The statement describes the catheter's approved indications: mapping, Type I atrial flutter in patients 18 or older, recurrent symptomatic paroxysmal atrial fibrillation under certain conditions, and drug refractory recurrent symptomatic persistent atrial fibrillation when used with compatible three-dimensional electroanatomic mapping systems. It also states the device provides real-time contact force measurement and location information with the CARTO 3 System. These descriptions are the source statement's reported purpose and are not independent proof of safety or effectiveness.
FDA approval order statement
The Biosense Webster THERMOCOOL SMARTTOUCH SF Uni-/Bi-DirectionalNavigation Catheter and related accessory devices are indicated for catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with a compatible RF generator, for the treatment of: Type I atrial flutter in patients age 18 or older. Recurrent symptomatic paroxysmal atrial fibrillation, when used with compatible three-dimensional electroanatomic mapping systems, as an alternative to antiarrhythmic drug therapy, or as an initial rhythm control strategy. Drug refractory recurrent symptomatic persistent atrial fibrillation (defined as continuous atrial fibrillation that is sustained beyond 7 days but less than 1 year), refractory or intolerant to at least one Class I or III antiarrhythmic medicine, when used with compatible three-dimensional electroanatomic mapping systems.The Biosense Webster THERMOCOOL SMARTTOUCH SF Uni-/Bi-DirectionalNavigation Catheter provides a real-time measurement of contact force between the catheter tip and the heart wall, as well as location information when used with the CARTO 3 System.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 2, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P030031/S142
- Regulatory pathway
- PMA supplement
- Applicant
- Biosense Webster, Inc.
- Product code
- OAD
- Decision code
- APPR
- Decision date
- Sep 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter.
- Applicant
- Biosense Webster, Inc.
- Product code
- OAD
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P030031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030031 · Original PMA
BIOSENSE WEBSTER NAVISTAR/CELSIUS THERMO COOL DIAGNOSTIC/ABLATION DEFLECTABLE TIP CATHETERS
P030031/S142 received
Application receipt date recorded by FDA.
P030031/S142 · FDA decision
Normal 180 Day Track
P030031/S146 · Related supplement
EZ STEER THERMOCOOL NAV BI-DIRECTIONAL ELECTROPHYSIOLOGY CATHETER; THERMOCOOL SMARTTOUCH BI-DIRECTIONAL NAVIGATION CATHE
Timeline entries are records held by MedtechLedger for P030031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA approval | Nov 5, 2004 | FDA | |
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Explore the linked device profile
Other records with product code OAD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Therapy Dual-8 Ablation CatheterP040042/S060 | Irvine Biomedical,Inc.(Ibi) | PMA supplement | Sep 3, 2026 | FDA |
| Irvine Biomedical,Inc.(Ibi) | PMA approval | Nov 18, 2005 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biosense Webster, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P030031/S142
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records